

CURRICULUM VITAE

Dr. Stefano Ugel

Born at Oderzo (Italy); 24 March 1980

Codice Fiscale: GLUSFN80C24F999V

Position: Associate Professor

Work address: Immunology section
Department of Medicine, University of Verona
Policlinico G.B. Rossi, Edificio D
P.le L.A. Scuro n.10
37135 Verona (Italy)



Phone: +39 0458126451

email: sugel80@gmail.com
stefano.ugel@univr.it

ORCID: 0000-0002-6639-7608

Web of Science ResearcherID: J-5535-2016

Scopus Author Identifier: 14120516300

EDUCATION

Dr. Stefano Ugel has 21 years (2003-2024) of laboratory experience. He started (2003-2004) as bachelor degree student in Biology at Department of Oncology and Surgical Science University of Padova with the thesis: "*Development of an efficient vaccination protocol towards p15E antigen in prostate tumor mouse model*" (108/110). After that he was selected for PhD-program in Oncology and Surgical Science, obtaining a PhD in 2008, with the thesis "*Active and passive immunotherapeutic approaches targeting Telomerase in mouse tumor models*". This program was carried out at the Department of Oncology and Surgical Science (Prof. P. Zanovello), University of Padova. From 2008, Dr Ugel has obtained a pluriennial post-doctoral fellowship: he won PhD fellowship "Volontari Comitato Veneto" (2008-2009) supported by AIRC to complete the project "*Generation of specific Telomerase cytotoxic T lymphocytes*" at Prof. Vincenzo Bronte laboratory (IOV - Istituto Oncologico Veneto - I.R.C.C.S.); next he won a PhD fellowship to complete the project "*New anti-tumor drugs able to support a better intra-tumor lymphocytes infiltration*" (2009-Oct 2010) at Prof. Vincenzo Bronte laboratory (VIMM – Venetian Institute of Molecular Medicine, University of Padova). Successively, he won a PhD fellowship for Abroad (2010) supported by AIRC to complete the project "*TEM-1 positive cells: a new target for cancer immunotherapy*" as postdoctoral researcher in George Coukos' laboratory at Ovarian Cancer Research Center (ORCR) of University of Pennsylvania, 421 Curie Boulevard 19104 Philadelphia (PA) United States (USA). Then Dr. Ugel was integrated as PhD in the project DOD BRCA "*BRCA expression in ovarian*

cancer" (rif. 553952) until May 2012. Then Dr. Ugel, as senior PhD, works at Immunology Section of Department of Medicine of Verona University, managed by Prof. Vincenzo Bronte (June 2012-2016). From November 2016 to October 2019, Dr. Ugel was enrolled as Tenure-track Assistant Professor at Department of Medicine, Immunology Section of University of Verona. April 2017, Dr. Ugel obtained Abilitazione Scientifica Nazionale (ASN, bando 1532/2016, SS06/A2 for General and Clinic Pathology). From November 2019, Dr. Ugel was enrolled as Assistant Professor at Department of Medicine, Immunology Section of University of Verona. April 2021, Dr. Ugel obtained Abilitazione Scientifica Nazionale for Full Professor (ASN, bando 1532/2016, SS06/A2 for General and Clinic Pathology). From February 2022, Dr. Ugel holds the position of University manager of the Immunology section of the Department of Medicine coordinated by Prof. Giovanni Gambaro, since the Director Prof. Vincenzo Bronte being on leave from work. From 2023, Dr. Stefano Ugel has been registered with the Order of Biologists of Veneto, Friuli Venezia Giulia and Trentino Alto Adige, with the following number Tri_A3428.

SCIENTIFIC ACTIVITY

Dr. Stefano Ugel research is based on:

- Validation of active immunotherapeutic approaches based on different vaccination setting using DNA plasmid in association with electric gene transfer, dendritic cells pulsed with cell-lysate or peptide, emulsinated peptide and also xenogenic vaccine
- Identification of immunodominant peptide of new tumor associated antigen.
- Validation of specific immune suppressive mechanisms in tumor tolerance.
- MDSC characterization in different tumor mouse models and human setting.
- Validation of passive immunotherapeutic approaches based on adoptive antigen specific CD8⁺ T cell transfer and isolation of specific high avidity CTL.
- Validation of new drugs able to selectively eliminate cells with of regulatory abilities, such as MDSCs, to increase the efficacy of cancer immunotherapy.
- Validation of immunotherapeutic approaches able to attack tumor endothelium.
- Generation humanized immune-reconstituted (HIR) mice model to define a specific human gene signature of early pro-metastatic niche.
- mRNA transfection to generate tolerogenic myeloid cells.
- Metabolic and epigenetic profiling of MDSCs

Dr. Stefano Ugel skills are:

- Cellular Biology: human and murine cellular culture, proliferation and cytotoxicity assays, lymphocytes isolation from spleens and tumors, in particular derivation of specific antigen CTL, transfection of cells to induce specific antigen expression, ELISA assays, ELISpot assays, cytofluorimetric analysis, such as intracytoplasmatic analysis of IFN γ . Evaluation of immune response after vaccination in mouse models in particular in prostate and melanoma tumor models. Phenotypic characterization and isolation by immunomagnetic sorting of specific cells.
- Molecular Biology: RNA and DNA extraction from different tissues, PCR, RT-PCR, Real Time PCR, gene cloning, western blot, protein purification in particular antibodies. Experience of gene expression by Affymetrix.
- Mouse handling.

- Computer skills and competences of Microsoft office tools (word, excel, power point) and also basic knowledge of graphic design applications (CorelDraw, CorelPhotoPaint, SigmaPlot, FlowJo).
- Technical practice of specific laboratory instruments: FacsCANTO, Elipot-Reader and BTX electroporator.
- Knowledge of English language.

Dr. Stefano training courses are:

- 2012 University of Verona: *"Corso di formazione per il personale C.I.R.S.A.L."*
- 2013 University of Verona: *"Formazione sui concetti generali in tema di prevenzione e sicurezza sul lavoro"*
- 2014 University of Verona: *"Corso di formazione generale alla SSL per Lavoratori"*
- 2014 Hospital of Trust of Verona: *"Gestione della sicurezza sul lavoro nella UOC di Immunologia"*
- 2016 University of Verona: *"Gestione della sicurezza nell'utilizzo degli agenti radiogeni"*
- 2016 University of Verona: *"Ruolo dei dispositivi di protezione collettiva nel laboratorio biologico e nel laboratorio di analisi"*
- 2016 Azienda Ospedaliera Universitaria Integrata di Verona: *"Attestato di idoneità tecnica per l'espletamento dell'incarico di addetto antincendio"*
- 2016 Istituto Oncologico Veneto (IOV): *"Horizon 2020 il nuovo programma quadro in ricerca e innovazione: come scrivere una proposta di successo in Horizon 2020"*
- 2019 Azienda Ospedaliera Universitaria Integrata di Verona: *"Sicurezza nell'uso dell'azoto liquido"*
- 2023 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZS): *"Biologia e gestione degli animali da laboratorio, moduli 3.1, 4, 5, 6.1, 7. dm 5 agosto 2021 roditori e lagomorfi (17 CFP)"*
- 2023 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZS): *"OPBA: formazione per i compiti, moduli 25, 50, 51 (12 CFP)"*
- 2023 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZS): *"Legislazione nazionale ed etica livello 1, moduli 1 e 2, dm 5 agosto 2021 (7.5 CFP)"*
- 2023 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZS): *"Etica e concezione dei progetti, moduli 9, 10, 11, dm 5 agosto 2021 (9 CFP)"*
- 2023 BioMedia: *"Modulo 1 - Legislazione Nazionale (3 CFP)"*
- 2023 BioMedia: *"Modulo 2 - Etica, benessere degli animali e Tre R (livello 1) (2 CFP)"*
- 2023 BioMedia: *"Modulo 3.1 - Biologia appropriata di base (teoria) Specie topo e ratto (5 CFP)"*
- 2023 BioMedia: *"Modulo 4 - Cura, salute e gestione degli animali (teoria) Specie topo e ratto (5 CFP)"*
- 2023 BioMedia: *"Modulo 6.1 - Metodi umanitari di soppressione (2 CFP)"*
- 2023 BioMedia: *"Modulo 9 - Etica, benessere degli animali e Tre R (livello 2) (2 CFP)"*
- 2023 BioMedia: *"Modulo 10 - Concezione di procedure e progetti (livello 1) (2 CFP)"*
- 2023 BioMedia: *"Modulo 11 - Concezione di procedure e progetti (livello 2) (2 CFP)"*
- 2023 BioMedia: *"Modulo 20 - Anestesia per procedure minori e procedure avanzate (3 CFP)"*
- 2023 BioMedia: *"Modulo 21 - Anestesia per procedure minori e procedure avanzate (2 CFP)"*
- 2023 BioMedia: *"Modulo 22 - Principi di chirurgia (4 CFP)"*
- 2023 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER): *"Etica e concezione dei progetti, moduli 9, 10, 11, dm 5 agosto 2021" (9 ECM).*

- 2023 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER): "Legislazione nazionale ed etica livello 1, moduli 1 e 2, dm 5 agosto 2021" (7,5 ECM)
- 2023 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER): "OPBA: formazione per i compiti, moduli 25, 50, 51" (12 ECM)

Congress Poster

- Cingarlini S., **Ugel S.**, Marigo I., De Santo C., Dolcetti L., Gallina G., Bronte V., and Zanovello P. *Preserved effective Env responsiveness in TRAMP mice*. SIICA, Ischia (Italy); 2005. **Selected for oral presentation.**
- **Ugel S.**; Cingarlini S.; Mesa Pardillo C.; Cipriani B.; Mennuni C.; Cerino R.; Calvaruso F.; Scarselli E.; Iezzi M.; Musiani P.; Zanovello P. and Bronte V. *Induction of telomerase-specific cytotoxic T cells by recombinant vaccines*. SIC, Bari (Italy); 2006.
- Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Cingarlini S., **Ugel S.**, Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Biciato S. and Bronte V. *Tumor-induced IL-4R α ⁺ inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells*. SIICA, Paris (France); 2006.
- Dolcetti L., Gallina G., De Santo C., Marigo I., Serafini P., Cingarlini S., **Ugel S.**, Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Biciato S. and Bronte V. *IL-4R α ⁺ is a marker of a subset cells of inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells*. The Potent New Anti-Tumor Immunotherapies. Keystone Symposia on Molecular Biology, Fairmont Banff Springs. Banff (Alberta); 2007.
- **Ugel S.**, Peranzoni E., Marigo I., Dolcetti L., Sonda N., Mantelli B., Papalini F., Zilio S., Mennuni C., Scarselli E., De Palma R., Zanovello P., and Bronte V. *Adoptive immunotherapy for cancer based on mTERT specific CD8⁺ T cells*. SIICA, Roma (Italy), 2008.
- Marigo I., Fernandez-Gomez A., Mandruzzato S., Francescato S., Valpione S., Perini P., Rinaldi L., Gallo P., **Ugel S.**, Zanovello P. and Bronte V. *MDSC: potential therapeutic role in autoimmune diseases*. FISM Synphosia, Roma (Italy), 2008. **Selected for oral presentation**
- Martini M., Testi M.G., Pasetto M., Picchio M.C., Innamorati G., Mazzocco M., **Ugel S.**, Cingarlini, Bronte V., Zanovello P., Krampera M., Mosna F., Cestari T., Riviera A.P., Brutti N., Barbieri O., Matera L., Tridente G., Colombatti M. and Sartoris S. *IFN- γ mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer*. 2nd European Congress of Immunology Berlin (Germany), 2009.
- Dolcetti L., Peranzoni E., **Ugel S.**, Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., Grassi F. and Bronte V. *Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF*. 2nd European Congress of Immunology Berlin (Germany), 2009. **Selected for oral presentation**
- **Ugel S.**, Rueter J., De Sanctis F., Scarselli E., Mennuni C., La Monica N., Coukos G. and Facciabene A. *mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion*. Gene Vaccination in Cancer, Ascoli Piceno (Italy), 2011.
- **Ugel S.**, Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Immune tolerance to tumor antigens occurs in a specialized environment of the spleen*. SIC, Bologna (Italy), 2012.
- Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura

- M.I., Bronte V.* and **Ugel S.*** *Anti-telomerase adoptive cell therapy to target B-cell lymphocytic leukemia*. CIMT, Mainz (Germany), 2013.
- De Sanctis F., **Ugel S.**, Fassan M., Iezzi M., Boschi F., Youngkyu P., Stramucci L., Lamolinara A., Sandri S., Ferrarini G., Cristovao Borges L., Sartoris S., Sbarbati A., Tuveson D., Scarpa A. e Bronte V. *Targeting telomerase in pancreatic cancer*. NIBIT, Siena (Italy), 2014.
 - **Ugel S.**, Facciponte J.G., De Sanctis F., Li C, Wang L., Nair G., Sehgal S., Raj A. ,Matthaiou E., Coukos G. and Facciabene A. *Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature*. NIBIT, Siena (Italy), 2014.
 - Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.* and **Ugel S.*** *Targeting B-cell lymphocytic leukemia by adoptive transfer of telomerase specific T cells*. PIVAC, Roma (Italy), 2014. (winner as best poster as provided: Signori E, Cavallo F. *The Fourteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-14), September 24-26, 2014, Rome, Italy: rethinking anti-tumor vaccines in a new era of cancer immunotherapy*. Cancer Immunol Immunother. 2015).
 - Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.* and **Ugel S.*** *Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies*. CMIT, Mainz (Germany), 2016.
 - Trovato R., De Sanctis F., Fiore A., Sandri S., Sartori S., Poffe O., Anselmi C., Fracasso G., Iezzi M., Lamolinara A., Fassan M., Rusev B., Scarpa A., Boschi F., Ruggeri L., Tuveson D., Sartoris S., **Ugel S.** and Bronte V. *Tumor-infiltrating myeloid cells in pancreatic ductal adenocarcinoma*. Regulatory Myeloid-Suppressor Cell Conference, Philadelphia (USA), 2016.
 - De Sanctis F., Fassan M, Lamolinara A., Iezzi M., Boschi F., Sbarbati A., Youngkyu P., Sandri S., Trovato R., Fiore A., Sartori S., Poffe O., Fracasso G., Anselmi C., Tuveson D, Lawlor R.T., Scarpa A., Sartoris S., **Ugel S.** and BronteV. *Telomerase specific adoptive cell therapy in pancreatic cancer*. NIBIT, Siena (Italy), 2016.
 - De Sanctis F., **Ugel S.** Fassan M., Lamolinara A., Iezzi M., Boschi F., Sbarbati A., Youngkyu P., Sandri S., Trovato R., Fiore A., Sartori S., Poffe O., Cestari T., Anselmi C., Tuveson D, Lawlor R.T., Scarpa A., Sartoris S. and BronteV. *Telomerase adoptive cell transfer in pancreatic cancer*. SIC, Verona (Italy), 2016.
 - Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.* and **Ugel S.*** *Feasibility of Telomerase-Specific Adoptive T-cell Therapy for Hematologic and Solid Malignancies*. SIC, Verona (Italy), 2016.
 - Fiore A., **Ugel S.**, De Sanctis F., Sandri S., Fracasso G., Trovato R., Sartoris S., Solito S., Mandruzzato S., Vascotto F., Hippen K.L., Mondanelli G., Grohmann U., Piro G., Carbone C., Melisi D., Lawlor R.T., Scarpa A., Lamolinara A., Iezzi M., Fassan M., Biciatto S., Blazar R., Sahin U., Murray P.J. and Bronte V. *FLIP controls immune regulatory transcriptional program in suppressive monocytes by canonical NF- κ B activation*. EMDS, Verona (Italy), 2018.
 - Trovato R., Fiore A., Sartori S., Giugno R., Cascione L., Canè S., De Sanctis F., Poffe O., Anselmi C., Hofer F., Sartoris S., Paiella S., Salvia R., Rusev B., Lawlor R.T., Solito S., Mandruzzato S., Bassi C., Scarpa A., Bronte V. and **Ugel S.** *Characterization of circulating and tumor-infiltrating myeloid-derived suppressor cells in patients affected by pancreatic ductal adenocarcinoma*. EMDS, Verona (Italy), 2018.
 - Trovato R., Fiore A., Sartori S., Giugno R., Cascione L., Canè S., De Sanctis F., Poffe O., Anselmi C., Hofer F., Sartoris S., Paiella S., Salvia R., Corbo V., Lawlor R.T., Solito S.,

- Pinton L., Mandruzzato S., Bassi C., Scarpa A., Bronte V. and **Ugel S.** *Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3*. CMIT, Mainz (Germany), 2019.
- Marigo I., Trovato R., Hofer F., Ingangi V., Desantis G., Leone K., De Sanctis F., Ugel S., Canè S., Simonelli A., Lamolinara A., Iezzi M., Fassan M., Rugge M., Boschi F., Borile G., Eisenhaure T., Sarkizova S., Lieb D., Hacohen N., Azzolin L., Piccolo S., Lawlor R., Scarpa A., Carbognin L., Bria E., Biciato S., Murray P.J., Bronte V. *Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages*. NIBIT, Virtual Meeting, 2020.
 - Frusteri C., Adamo A., Pilotto S., Caligola S., Belluomini L., Poffe O., Rizzini D., Giacobazzi L., Vella A., Canè S., Dusi S., Sartori G., Insolda J., Sposito M., Incani U., Carbone C., Piro G., Pettinella F., Sartoris S., De Sanctis F., Scapini P., Dusi S., Cassatella MA, Bria E., Milella M., Bronte V., Ugel S. *Immune checkpoint blockade mitigates systemic inflammation and affects cellular FLIP-expressing myeloid-derived suppressor cells in non-small cell lung cancer patients*. NIBIT, Padova (Italy), 2022. (**winner as best poster**).
 - Canè S., Barouni R., Fabbi M., Cuozzo J., Fracasso G., Adamo A., Ugel S., Trovato R., De Sanctis F., Giacca M., Lawlor R., Scarpa S., Rusev B., Lionetto G., Paiella S., Salvia R., Bassi C., Mandruzzato S., Ferrini S., and Bronte V. *Neutralization of NET-associated human ARG1 enhances cancer immunotherapy*. NIBIT, Padova (Italy), 2022.
 - Musiu C., Adamo A., Caligola S., Frusteri C., Lupo F., Boschi F., Busato M., Poffe O., Anselmi C., Vella A., Wang T., Piro G., Carbone C., Marzola P., D'Onofrio F., Crinò S., Corbo V., Scarpa A., Salvia R., Bassi C., Bronte V., Ugel S., Sartoris S., Paiella S., and De Sanctis F. *Local thermal ablation breaks immune tolerance in pancreatic cancer*. NIBIT, Padova, 2022.
 - De Sanctis F., Lamolinara A., Boschi F., Musiu C., Caligola S., Trovato R., Fiore A., Frusteri C., Anselmi C., Poffe O., Cestari T., Canè S., Sartoris S., Giugno R., Del Rosario G., Zappacosta B., Del Pizzo F., Fassan M., Dugnani E., Piemonti L., Bottani E., Decimo I., Lawlor R., Corbo V., Park Y., Tuveson D., Bassi C., Scarpa A., Iezzi M., Ugel S., and Bronte V. *Interrupting the nitrosative stress fuels tumour-specific cytotoxic T lymphocytes in pancreatic cancer*. NIBIT, Padova (Italy), 2022.
 - Adamo A., Frusteri C., Pilotto S., Caligola S., Belluomini L., Poffe O., Rizzini D., Giacobazzi L., Vella A., Canè S., Dusi S., Sartori G., Insolda J., Sposito M., Incani U., Carbone C., Piro G., Pettinella F., Sartoris S., De Sanctis F., Scapini P., Dusi S., Cassatella MA, Bria E., Milella M., Bronte V., **Ugel S.** *Immune checkpoint blockade mitigates systemic inflammation and affects cellular FLIP-expressing myeloid-derived suppressor cells in non-small cell lung cancer patients*. CICON, Milano (Italy), 2023.
 - Canè S., Barouni R.M., Fabbi M., Cuozzo J., Fracasso G., Adamo A., **Ugel S.**, Trovato R., De Sanctis F., Giacca M., Lawlor R., Scarpa A., Rusev B., Lionetto G., Paiella S., Salvia R., Bassi C., Mandruzzato S., Ferrini S., Bronte V. *Neutralization of NET-associated human ARG1 enhances cancer immunotherapy*. CICON, Milano (Italy), 2023.
 - Musiu C., Adamo A., Caligola S., Frusteri C., Lupo F., Boschi F., Busato M., Poffe O., Anselmi C., Vella A., Wang T., Piro G., Carbone C., Marzola P., D'Onofrio F., Crinò S., Corbo V., Scarpa A., Salvia R., Bassi C., Bronte V., **Ugel S.**, Sartoris S., Paiella S., and De Sanctis F. *Immunomodulation by local thermal ablation in pancreatic cancer*. CICON, Milano (Italy), 2023. C
 - Caligola S., Giacobazzi L., Canè S., Vella A., Adamo A., **Ugel S.**, Giugno R., Bronte V. *GateMeClass: Gate Mining and Classification of Cytometry Data*. VII Congresso Nazionale ISCAA , Verona (Italy), 2024.

Oral presentation at international/national congress

- **Ugel S.**, Mennuni C., Mori F., Cipriani B., Iezzi M., Pannellini T., Lazzaro D., Ciliberto G., La Monica N., Zanovello P., Bronte V., and Scarselli E. *Immunosurveillance by telomerase-based vaccination*. SIICA, Roma (Italy), 2008. **(selected)**
- **Ugel S.**, Peranzoni E., Piccoli M., Falisi E., Papalini F., Solito S., Cabrelle A., De Coppi P., Zanovello P., Mandruzzato S and Bronte V. *Rational and successful chemo-immunotherapy: unveiling a novel immune adjuvant property of chemotherapeutic drugs based on the perturbation of myeloid suppressor biological niche*. SIICA, Bari (Italy), 2010. **(selected)**
- **Ugel S.**, Faccioponti J., De Sanctis F., Mitrousis N., Wang L., Nair G., Coukos G. and Facciabene A. *Gene based vaccination specific for TEM1 (Endosialin/CD248) controls tumor progression inducing a specific T cell response*. Gene Vaccination in Cancer, Ascoli Piceno (Italy), 2011. **(selected)**
- **Ugel S.**, Rueter J., De Sanctis F., Scarselli E., Mennuni C., La Monica N., Coukos G. and Facciabene A. *mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion*. TRCCC, Seven Springs (USA), 2012. **(selected)**
- **Ugel S.** *Overcoming Physical Barriers to Cancer Immunotherapy*. 2nd Inflammation, Cancer and Novel Therapeutics Conference & Summer School 2012. Heraklion (Greece), 2012. **(invited)**
- **Ugel S.**, Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Myeloid Derived Suppressive Cells: Overcoming Physical Barriers to Cancer Immunotherapy*. InsPiRE Conference "Progress in combination therapy in cancer using novel immunomodulators", Athen (Greece), 2012. **(invited)**
- **Ugel S.** *Modulation of tumor microenvironment by chemotherapy*. 10th Annual Meeting, NIBIT, Certosa di Pontignano (SI) (Italy), 2012. **(invited)**
- **Ugel S.** *Terapia adottiva con cellule TERT specifiche nelle neoplasie ematologiche*. Giornata SIES (Società Italiana Ematologia Sperimentale), a Verona (VR) (Italy), 2017. **(invited)**
- **Ugel S.** *Riprogrammazione genetica delle cellule dell'immunità adattativa ed innata per approcci di immunoterapia*. XV Congresso SIES (Società Italiana Ematologia Sperimentale), Rimini (RN) (Italy), 2018. **(invited)**
- **Ugel S.** *L'era dell'ImmunOncologia, ovvero l'immunoterapia applicata al trattamento dei tumori, una storia vincente dal banco dello sperimentatore al letto del paziente*. XXIV Edizione del Premio Laccetti Associazione Umbra per la lotta Contro il Cancro Onlus (AUCC), Perugia (PG) (Italy) 2019. **(invited)**
- **Ugel S.** *Baricitinib restrains the immune dysregulation in severe COVID-19 patients*. 18th Annual Meeting, NIBIT, Virtual Meeting, 2020. **(selected)**
- **Ugel S.** *FLIP-expressing cells: angel or demon?* VI Congresso Nazionale ISCAA (Società Italiana per l'Analisi Citometrica Cellulare), Catania (CT) (Italy), 2022. **(invited)**
- **Ugel S.** *FLIP-reprogramming of myeloid cells in suppressive cells*. VIII Congresso Nazionale ISCAA (Società Italiana per l'Analisi Citometrica Cellulare), Verona (VR) (Italy), 2024. **(invited)**
- **Ugel S.** *The yin-yang of FLIP-expressing myeloid cells as a target for developing cancer therapy & a tool to dampen immunopathology*. PhD seminars for Faculty of Medical Sciences (Radboudumc), Radboud University, Nijmegen, The Netherlands **(invited)**

International scientific congress organization

- 2018, Member of scientific commitment of international congress of EMDS society (European Society of Dendritic cells and Macrophages): "The cross-road between macrophages and dendritic cells. From immunometabolism to single cell fate". 27-29 September, Verona (VR) (Italy)

Funding

- 2018_ **MyFirst AIRC grant** supported by Associazione Italiana per la Ricerca sul Cancro (AIRC): Principal Investigator of project entitled "FLIP up-regulation on myeloid cells promotes tumor development" (2019-2023; 474.650,00€); project number: 21509
- 2018_ **PRIN2017** (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale): coordinator of research unit of the project entitled: "Novel IDO1 inhibitors at the forefront of cancer immunotherapy: from compound screening to preclinical validation in pancreatic ductal adenocarcinoma and glioblastoma multiforme" (2019-2021; 190.000,00€, CUP: B38D19000140006); project number: 2017WJZ9W9.
- 2022_ **National Center for Gene Therapy and Drugs based on RNA Technology (CN3 RNA)** supported by coordinator of research unit for University of Verona (2022-2025; 1.195.375,07€; CUP: B33C22000630001)
- 2023_ **Bridge AIRC grant** supported by Associazione Italiana per la Ricerca sul Cancro (AIRC): Principal Investigator of project entitled "The epigenetic, transcriptomic and metabolic roadmap of FLIP-reprogrammed monocytes in cancer" (2024; 99.200€); project number: 28730.
- 2025_ **Investigator Grant AIRC** (IG grant) supported by Associazione Italiana per la Ricerca sul Cancro (AIRC): Principal Investigator of project entitled "Tumor-Hijacked Monocytes Awaken Dormant Cancer Cells and Foster Widespread Metastatization-THE EVIL CREW" (2026-2030; 1.024.000,00€); project number: 32017.

Patents

- 2017: **Ugel S.**, Fiore A., Sahin U. and Bronte V. Engineered cells for inducing tolerance. Biontech (Mainz, DE), PCT/EP2017/051068.
- 2023: **Ugel S.**, Sandri S., Bobisse S., Bronte V. Gene sequence encoding a mouse TCR specific for the human HLA-A2 complex and hTERT₈₆₅₋₈₇₃ peptide and its use for engineering human T lymphocytes for adoptive cell therapy of cancer. University of Verona, European patent EP3271384.

Awards and honors

- November 2006: Winner of the Prize "Laura Polo" for best bachelor thesis in Oncology awarded by the University of Padova, Italy.
- August 2010: Winner of Start-Up Veneto 2010 "La notte degli angeli" with the scientific group Safespring of the University of Padova to develop an innovative technology to make water drinkable; Padova (Italy)
- September 2011: Winner of the prize as best poster of under-35 researcher awarded by Gene Vaccination in Cancer, Ascoli Piceno (Italy)
- September 2014: Winner of the prize as the best poster (as special mention) of under-35 research awarded by EACR at the 14th International Conference on Progress in Vaccination Against Cancer (PIVAC-14), Rome (Italy) as testified by a publication published in Cancer Immunol Immunother. 2015, 64(10):1349-56
- August 2018: Winner of Start-Up Veneto 2018 (first selection) with the scientific group AVATAR of the University of Verona to develop an innovative tool for developing and testing innovative anti-cancer immunotherapy; Padova (Italy)

Books

- De Sanctis F., Bronte V, **Ugel S.** *Tumor-induced Myeloid-derived Suppressor Cells*. In: Myeloid Cells in Health and Disease: A Synthesis, 2015, ASM Press.

Publications

1. **Ugel S.**, Gupta A., Spiteri G., Marchetti P., De Sanctis F., Wouters S., Konnova A., Monaco M.G.L., Carta A., Pezzani M.D., Liviero F., Pavanello S., dell'Omo M., Fabiánová E., Béréšová J., Larese Filon F., Mauro M., Verlato G., Bronte V., Kumar-Singh S., Porru S. *A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2- ORCHESTRA Project*. *Frontiers in Immunology*. 2025 Nov 25;16:1707449. PMID: 41376637
<https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1707449/full>
(Impact factor: 5.9)
2. Cheng X.F., Lucas B., Lampe P., **Ugel S.**, Chen S., Unger A., Bischoff M., Adariani S.R., Naredla K.R., Kumar K., Schmidt A., Strohmam C., Janning P., Gasper R., Lucas M., Gersch M., Sievers S., Bronte V., Ziegler S., Waldmann H. *Design, Synthesis, and Structural Evolution of Pseudo-Natural Product IDO1 Inhibitors and Degradors*. *Angewandte Chemie International Edition*. 2025 Nov 27:e18753. PMID: 41310997
<https://onlinelibrary.wiley.com/doi/10.1002/anie.202518753> (Impact factor: 17)
3. Danzi F., Butera G., Sutton D., Perricone M.D., Hu Y., Celesia A., Manfredi M., Brandi J., Pourmandi N., Nelson N.S., Lin L., Bevere M., Pacchiana R., Pea A., Salvia R., Scarpa A., Luchini C., Cecconi D., **Ugel S.**, Lyssiotis .CA., Fiore A., Donadelli M. *Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells*. *Cell Death & Disease*. 2025 Oct 27;16(1):766. PMID: 4114548
<https://www.nature.com/articles/s41419-025-08082-1> (Impact factor: 9.6)

4. Musiu C., Adamo A., Caligola S., Agostini A., Frusteri C., Lupo F., Boschi F., Busato A., Poffe O., Anselmi C., Vella A., Wang T., Dusi S., Piro G., Carbone C., Tortora G., Marzola P., D'Onofrio M., Crinò S.F., Corbo V., Scarpa A., Salvia R., Malleo G., Lionetto G., Sartoris S., **Ugel S.**, Bassi C., Bronte V., Paiella S., De Sanctis F. *Local ablation disrupts immune evasion in pancreatic cancer*. Cancer Letters. 2025 Jan 28; 609:217327. PMID: 39580047 (corresponding author). <https://www.sciencedirect.com/science/article/pii/S0304383524007225?via%3Dihub> (Impact factor: 9.1)
5. Carbone C., De Luca R., Puca E., Agostini A., Caggiano A., Priori L., Esposito A., Ascrizzi S., Piro G., Salvatore L., De Sanctis F., **Ugel S.**, Corbo V., Neri D., Tortora G. *Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice*. Journal of Experimental & Clinical Cancer Research. 2025 Jan 7;44(1):7. PMID: 39773310. <https://jeccr.biomedcentral.com/articles/10.1186/s13046-024-03238-x> (Impact factor: 11.4)
6. Esposito A., Agostini A., Quero G., Piro G., Priori L., Caggiano A., Scaglione G., Battaglia A., Calegari M.A., Salvatore L., Bensi M., Maratta M.G., Ceccarelli A., Trovato G., Genovese G., Gurreri E., Ascrizzi S., Martini M., Fiorillo C., Fattorossi A., De Sanctis F., **Ugel S.**, Corbo V., Alfieri S., Tortora G., Carbone C. *Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance*. Cell Death & Disease. 2024 Dec 4;15(12):878. PMID: 39632825. <https://www.nature.com/articles/s41419-024-07266-5> (Impact factor: 8.1)
7. Panfili E., Rezzi S.J., Adamo A., Mazzeletti D., Massarotti A., Miggiano R., Fallarini S., Ambrosino S., Coletti A., Molinaro P., Milella M., Paiella S., Macchiarulo A., **Ugel S.**, Piralì T., Pallotta M.T. *Identification of a Compound Inhibiting Both the Enzymatic and Nonenzymatic Functions of Indoleamine 2,3-Dioxygenase 1*. ACS Pharmacology & Translational Science. 2024 Sep 12;7(10):3056-3070. PMID: 39421661. <https://pubs.acs.org/doi/10.1021/acsptsci.4c00265> (Impact factor: 5.1)
8. Belluomini L., Cesta Incani U., Smimmo A., Avancini A., Sposito M., Insolda J., Mariangela Scaglione I., Gattazzo F., Caligola S., Adamo A., Conciatori F., Bazzichetto C., **Ugel S.**, Giannarelli D., Pilotto S., Milella M. *Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation*. Lung Cancer. 2024 Aug;194:107893. PMID: 39008934. <https://www.sciencedirect.com/science/article/pii/S0169500224004276?via%3Dihub> (Impact factor: 4.5)
9. Sposito M., Eccher S., Pasqualin L., Scaglione I.M., Avancini A., Tregnago D., Trestini I., Insolda J., Bonato A., **Ugel S.**, Derosa L., Milella M., Pilotto S., Belluomini L. *Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutic implications*. Expert Review of Clinical Immunology. 2024 Jun 26:1-12. PMID: 38913940. <https://www.tandfonline.com/doi/full/10.1080/1744666X.2024.2372327>. (Impact factor: 3.9)
10. Musiu C., Lupo F., Agostini A., Lionetto G., Bevere M., Paiella S., Carbone C., Corbo V., **Ugel S.***, De Sanctis F*. *Cellular collusion: cracking the code of immunosuppression and chemoresistance in PDAC*. Frontiers in Immunology. 2024 May 16;15:1341079. PMID: 38817612 (* equal contribution). <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1341079/full>. (Impact factor: 5.7)

11. Caligola S., Giacobazzi L., Canè S., Vella A., Adamo A., **Ugel S.**, Giugno R., Bronte V. *GateMeClass: Gate Mining and Classification of cytometry data*. *Bioinformatics*. 2024 May 2;40(5):btac322. PMID: 38775676. (corresponding author) <https://academic.oup.com/bioinformatics/article/40/5/btac322/7679648?login=true>. (Impact factor: 4.4)
12. De Sanctis F., Dusi S., Caligola S., Anselmi C., Petrova V., Rossi B., Angelini G., Erdeljan M., Wöll S., Schlitter A.M., Metzler T., Steiger K., Borok Z., Bailey P., Bauer A., Halin C., Boschi F., Giugno R., Canè S., Lawlor R., Corbo V., Scarpa A., Constantin G., **Ugel S.**, Vascotto F., Sahin U., Türeci Ö., Bronte V. *Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer*. *Immunity*. 2024 Jun 11;57(6):1378-1393.e14. PMID: 38749447. <https://www.sciencedirect.com/science/article/pii/S1074761324002267?via%3Dihub> (Impact factor: 25.5)
13. Lupo F., Pezzini F., Pasini D., Fiorini E., Adamo A., Veghini L., Bevere M., Frusteri C., Delfino P., D'agosto S., Andreani S., Piro G., Malinova A., Wang T., De Sanctis F., Lawlor R.T., Hwang C.I., Carbone C., Amelio I., Bailey P., Bronte V., Tuveson D., Scarpa A., **Ugel S.**, Corbo V. *Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC*. *Gut*. 2024 Apr 26;gutjnl-2023-329807. PMID: 38670629. <https://gut.bmj.com/content/early/2024/04/24/gutjnl-2023-329807.long>. (Impact factor: 23)
14. Gambino S., Quaglia F.M., Galasso M., Cavallini C., Chignola R., Lovato O., Giacobazzi L., Caligola S., Adamo A., Putta S., Aparo A., Ferrarini I., **Ugel S.**, Giugno R., Donadelli M., Dando I., Krampera M., Visco C., Scupoli M.T. *B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression*. *Scientific Reports*. 2024 Mar 19;14(1):6595. PMID: 38503806. <https://www.nature.com/articles/s41598-024-55728-9>. (Impact factor: 3.8)
15. Agostini A., Guerriero I., Piro G., Quero G., Roberto L., Esposito A., Caggiano A., Priori L., Scaglione G., De Sanctis F., Sistigu A., Musella M., Larghi A., Rizzatti G., Lucchetti D., Alfieri S., Sgambato A., Bria E., Bizzozero L., Arena S., **Ugel S.**, Corbo V., Tortora G., Carbone C. *Talinflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer*. *Journal Translational Medicine*. 2023 Nov 23;21(1):843. PMID: 37996891. <https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04733-z>
16. Adamo A., Frusteri C., Pilotto S., Caligola S., Belluomini L., Poffe O., Giacobazzi L., Dusi S., Musiu C., Hu Y., Wang T., Rizzini D., Vella A., Canè S., Sartori G., Insolda J., Sposito M., Incani U.C., Carbone C., Piro G., Pettinella F., Qi F., Wang D., Sartoris S., De Sanctis F., Scapini P., Dusi S., Cassatella M.A., Bria E., Milella M., Bronte V., **Ugel S.** *Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients*. *Oncoimmunology*. 2023 Sep 14;12(1):2253644. PMID: 37720688 <https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2253644>
17. Pettinella F., Lattanzi C., Donini M., Cavegion E., Marini O., Iannoto G., Costa S., Zenaro E., Fortunato T.M., Gasperini S., Giani M., Belluomini L., Sposito M., Insolda J., Scaglione I.M., Milella M., Adamo A., Poffe O., Bronte V., Dusi S., Cassatella M.A., **Ugel S.**, Pilotto S., Scapini P. *Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood*

Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients. *Cancers (Basel)*. 2023 Nov 3;15(21):5285. PMID: 37958458. <https://www.mdpi.com/2072-6694/15/21/5285>

18. Andretto V., Dusi S., Zilio S., Repellin M., Kryza D., **Ugel S.***, Lollo G.* *Tackling TNF- α in autoinflammatory disorders and autoimmune diseases: From conventional to cutting edge in biologics and RNA- based nanomedicines.* *Advanced Drug Delivery Reviews*. 2023 Sep 1;201:115080. (* equal contribution) PMID: 37660747 <https://www.sciencedirect.com/science/article/pii/S0169409X23003952?via%3Dihub>
19. **Ugel S.**, Bazzichetto C., Conciatori F. *Editorial: Tailoring immunotherapy in gastrointestinal cancer: the role of circulating factors.* *Frontiers in Oncology*. 2023 Aug 8;13:1260183. PMID: 37614498 <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1260183/full>
20. Turri G., Caligola S., **Ugel S.**, Conti C., Zenuni S., Barresi V., Ruzzenente A., Lippi G., Scarpa A., Bronte V., Guglielmi A., Pedrazzani C. *Pre-diagnostic prognostic value of leukocytes count and neutrophil-to-lymphocyte ratio in patients who develop colorectal cancer.* *Frontiers in Oncology*. 2023 Jun 5;13:1148197. PMID: 37342188. <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1148197/full>
21. Salemme V., Vedelago M., Sarcinella A., Moietta F., Piccolantonio A., Moiso E., Centonze G., Manco M., Guala A., Lamolinara A., Angelini C., Morellato A., Natalini D., Calogero R., Incarnato D., Oliviero S., Conti L., Iezzi M., Tosoni D., Bertalot G., Freddi S., Tucci F.A., De Sanctis F., Frusteri C., **Ugel S.**, Bronte V., Cavallo F., Provero P., Gai M., Taverna D., Turco E., Pece S., Defilippi P. *p140Cap inhibits β -Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response.* *Nature Communications*. 2023 May 11;14(1):2350. PMID: 37169737. <https://www.nature.com/articles/s41467-023-37824-y>
22. Canè S., Barouni R.M., Fabbi M., Cuozzo J., Fracasso G., Adamo A., **Ugel S.**, Trovato R., De Sanctis F., Giacca M., Lawlor R., Scarpa A., Rusev B., Lionetto G., Paiella S., Salvia R., Bassi C., Mandruzzato S., Ferrini S., Bronte V. *Neutralization of NET-associated human ARG1 enhances cancer immunotherapy.* *Science Translational Medicine*. 2023 Mar 15;15(687):eabq6221. PMID: 36921034. https://www.science.org/doi/10.1126/scitranslmed.abq6221?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
23. Wang T., Hu Y., Dusi S., Qi F., Sartoris S., **Ugel S.***, De Sanctis F*. *"Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer.* *Frontiers in Immunology*. 2023 Feb 22;14:1130060. PMID: 36911674. (* equal contribution and corresponding authorship). <https://www.frontiersin.org/articles/10.3389/fimmu.2023.1130060/full>
24. Raccosta L., Marinozzi M., Costantini S., Maggioni D., Ferreira L.M., Corna G., Zordan P., Sorice A., Farinello D., Bianchessi S., Riba M., Lazarevic D., Provero P., Mack M., Bondanza A., Nalvarte I., Gustafsson J.A., Ranzani V., De Sanctis F., **Ugel S.**, Baron S., Lobaccaro J.A., Pontini L., Pacciarini M., Traversari C., Pagani M., Bronte V., Sitia G., Antonson P., Brendolan A., Budillon A., Russo V. *Harnessing the reverse cholesterol transport pathway to favor differentiation of monocyte-derived APCs and antitumor responses.* *Cell Death and Disease*. 2023 Feb 15;14(2):129. PMID: 36792589. <https://www.nature.com/articles/s41419-023-05620-7>

25. Piro G., Carbone C., Agostini A., Esposito A., De Pizzol M., Novelli R., Allegretti M., Aramini A., Caggiano S., Granitto A., De Sanctis F., **Ugel S.**, Corbo V., Martini M., Lawlor R.T., Scarpa A., Tortora G. *CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer*. *British Journal of Cancer*. 2022 Nov 16. PMID: 36385556. <https://www.nature.com/articles/s41416-022-02028-6>

26. Costa S., Bevilacqua D., Cavegion E., Gasperini S., Zenaro E., Pettinella F., Donini M., Dusi S., Constantin G., Lonardi S., Vermi W., De Sanctis F., **Ugel S.**, Cestari T., Abram C. L., Lowell C.A., Rodegher P., Tagliaro F., Girolomoni G., Cassatella M.C., Patrizia Scapini P. *Neutrophils inhibit $\gamma\delta$ T cell functions in the imiquimod-induced mouse model of psoriasis*. *Frontiers in Immunology*. 2022, Nov 15;13:1049079. PMID: 36466913. <https://www.frontiersin.org/articles/10.3389/fimmu.2022.1049079/full>

27. De Sanctis F., Adamo A., Canè S., **Ugel S.** *Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy*. *Seminars in Immunopathology*. 2022 Sep 26;1-24. PMID: 36161514. (corresponding authorship) <https://link.springer.com/article/10.1007/s00281-022-00965-1>

28. De Sanctis F., Lamolinara A., Boschi F., Musiu C., Caligola S., Trovato R., Fiore A., Frusteri C., Anselmi C., Poffe O., Cestari T., Canè S., Sartoris S., Giugno R., Del Rosario G., Zappacosta B., Del Pizzo F., Fassan M., Dugnani E., Piemonti L., Bottani E., Decimo I., Paiella S., Salvia R., Lawlor R.T., Corbo V., Park Y., Tuveson D.A., Bassi C., Scarpa A., Iezzi M., **Ugel S***, Bronte V*. *Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer*. *Journal for Immunotherapy of Cancer*. 2022. PMID: 35022194. (* equal contribution) <https://jitc.bmj.com/content/10/1/e003549.long>

29. Ferraccioli G., Gremese E., Goletti D., Petrone L., Cantini F., **Ugel S.**, Canè S., Bronte V. *Immune-Guided Therapy of COVID-19*. *Cancer Immunology Research*. 2022. PMID: 35074758. <https://aacrjournals.org/cancerimmunolres/article-abstract/10/4/384/689543/Immune-Guided-Therapy-of-COVID-19Immune-Guided?redirectedFrom=fulltext>

30. Calzetti F., Finotti G., Tamassia N., Bianchetto-Aguilera F., Castellucci M., Canè S., Lonardi S., Cavallini C., Matte A., Gasperini S., Signoreto I., Benedetti F., Bonifacio M., Vermi W., **Ugel S.**, Bronte V., Tecchio C., Scapini P., Cassatella MA. *CD66b⁺CD64^{dim}CD115⁻ cells in the human bone marrow represent neutrophil-committed progenitors*. *Nature Immunology*. 2022. PMID: 35484408. <https://www.nature.com/articles/s41590-022-01189-z>

31. Caligola S., De Sanctis F., Canè S., **Ugel S.** *Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies*. *Frontiers in Genetics*. 2022. PMID: 35651929. (corresponding authorship) <https://www.frontiersin.org/articles/10.3389/fgene.2022.867880/full>

32. Bellone M., Bregni M., Bronte V., **Ugel S.**, Ferrucci P.F., Di Nicola M., Nisticò P., Zuccolotto G., Rosato A., Russo V., Sica A., Colombo M.P. *Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy*. *Cancer*

33. Hofer F., Di Sario G., Musiu C., Sartoris S., De Sanctis F., **Ugel S.** *A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.* Cells. 2021 PMID: 34685679. (corresponding authorship) <https://www.mdpi.com/2073-4409/10/10/2700>

34. Musiu C., Caligola S., Fiore A., Lamolinara A., Frusteri C., Del Pizzo F.D., De Sanctis F., Canè S., Adamo A., Hofer F., Barouni R.M., Grilli A., Zilio S., Serafini P., Tacconelli E., Donadello K., Gottin L., Polati E., Girelli D., Polidoro I., Iezzi P.A., Angelucci D., Capece A., Chen Y., Shi Z.L., Murray P.J., Chilosi M., Amit I., Bicciato S., Iezzi M., Bronte V., **Ugel S.** *Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis.* Cell Death & Differentiation. 2021 PMID: 34518653. (corresponding authorship) <https://www.nature.com/articles/s41418-021-00866-0>

35. Aaboe Jørgensen M., **Ugel S.**, Linder Hübbe M., Carretta M., Perez-Penco M., Weis-Banke S.E., Martinenaite E., Kopp K., Chapellier M., Adamo A., De Sanctis .F, Frusteri C., Iezzi M., Zocca M.B., Hargbøll Madsen D., Wakatsuki Pedersen A., Bronte V., Andersen MH. *Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.* Cancer Immunology Research. 2021 PMID: 34518197. <https://aacrjournals.org/cancerimmunolres/article/9/11/1316/666198/Arginase-1-Based-Immune-Modulatory-Vaccines-Induce>

36. Carbone C., Piro G., Agostini A., Delfino P., De Sanctis F., Nasca V., Spallotta F., Sette C., Martini M., **Ugel S.**, Corbo V., Cappello P., Bria E., Scarpa A., Tortora G. *Intratumoral injection of TLR9 agonist promotes an immunopermissivemicroenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.* Journal for Immunotherapy of Cancer. 2021 PMID: 34479922. <https://jitc.bmj.com/content/9/9/e002876.long>

37. Mazzariol A., Benini A., Unali I., Nocini R., Smania M., Bertoncelli A., De Sanctis F., **Ugel S.**, Donadello K., Polati E., Gibellini D. *Dynamics of SARS-CoV2 Infection and Multi-Drug Resistant Bacteria Superinfection in Patients With Assisted Mechanical Ventilation.* Frontiers in Cellular and Infection Microbiology. 2021 PMID: 34458159. <https://www.frontiersin.org/articles/10.3389/fcimb.2021.683409/full>

38. Ciccocioppo R., Gibellini D., Astori G., Bernardi M., Bozza A., Chieragato K., Elice F., **Ugel S.**, Caligola S., De Sanctis F., Canè S., Fiore A., Trovato R., Vella A., Petrova V., Amodeo G., Santimaria M., Mazzariol A., Frulloni L., Ruggeri M., Polati E., Bronte V. *The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia.* Stem Cell Research & Therapy. 2021 Jun 2;12(1):316. PMID: 34078447. <https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02376-9>

39. **Ugel S.** and Bronte V. *Galectin-1 Supports a Dangerous Liaison between Monocytes and Multiple Myeloma.* Cancer Immunology Research. 2021 May;9(5):488. PMID: 33941534.

<https://aacrjournals.org/cancerimmunolres/article/9/5/488/666115/Galectin-1-Supports-a-Dangerous-Liaison-between>

40. Bost P., De Sanctis F., Canè S., **Ugel S.**, Donadello K., Castellucci M., Eyal D., Fiore A., Anselmi C., Barouni R.M., Trovato R., Caligola S., Lamolinara A., Iezzi M., Facciotti F., Mazzariol A., Gibellini D., De Nardo P., Tacconelli E., Gottin L., Polati E., Schwikowski B., Amit I., Bronte V. *Deciphering the state of immune silence in fatal COVID-19 patients.* Nature Communications. 2021 Mar 5;12(1):1428. PMID: 33674591. <https://www.nature.com/articles/s41467-021-21702-6>
41. Adamo A., Frusteri C., Pallotta M.T., Pirali T., Sartoris S., **Ugel S.** *Moonlighting Proteins Are Important Players in Cancer Immunology.* Frontiers in Immunology. 2021 Jan 18;11:613069. PMID: 33584695. (corresponding authorship) <https://www.frontiersin.org/articles/10.3389/fimmu.2020.613069/full>
42. **Ugel S.**, Canè S., De Sanctis F., Bronte V. *Monocytes in the Tumor Microenvironment.* Annual Review of Pathology: Mechanisms of Disease. 2021 Jan 24;16:93-122. PMID: 33497262. https://www.annualreviews.org/doi/10.1146/annurev-pathmechdis-012418-013058?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
43. Adamo A., Delfino P., Gatti A., Bonato A., Takam Kamga P., Bazzoni R., **Ugel S.**, Mercuri A., Caligola S., Krampera M. *HS-5 and HS-27A Stromal Cell Lines to Study Bone Marrow Mesenchymal Stromal Cell-Mediated Support to Cancer Development.* Frontiers in Cell Developmental Biology. 2020 Nov 5;8:584232. PMID: 33251214. <https://www.frontiersin.org/articles/10.3389/fcell.2020.584232/full>
44. Barouni R.M., Musiu C., Bronte V., **Ugel S.**, Canè S. *Phenotypical Characterization and Isolation of Tumor-Derived Mouse Myeloid-Derived Suppressor Cells.* Methods in Molecular Biology. 2021;2236:29-42. PMID: 33237538. https://link.springer.com/protocol/10.1007/978-1-0716-1060-2_4
45. Bronte V.*, **Ugel S.***, Tinazzi E., Vella A., De Sanctis F., Canè S., Batani V., Trovato R., Fiore A., Petrova V., Hofer F., Barouni R.M., Musiu C., Caligola S., Pinton L., Torroni L., Polati E., Donadello K., Friso S., Pizzolo F., Iezzi M., Facciotti F., Pelicci P.G., Righetti D., Bazzoni P., Rampudda M., Comel A., Mosaner W., Lunardi C., Olivieri O. *Baricitinib restrains the immune dysregulation in patients with severe COVID-19.* Journal of Clinical Investigations. 2020 PMID: 32809969 (* equal contribution). <https://www.jci.org/articles/view/141772>
46. Marigo I., Trovato R., Hofer F., Ingangi V., Desantis G., Leone K., De Sanctis F., **Ugel S.**, Canè S., Simonelli A., Lamolinara A., Iezzi M., Fassan M., Ruge M., Boschi F., Borile G., Eisenhaure T., Sarkizova S., Lieb D., Hacohen N., Azzolin L., Piccolo S., Lawlor R.T., Scarpa A., Carbognin L., Bria E., Biciato S., Murray P.J., Bronte V. *Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages.* Cancer Discovery. 2020 Nov;10(11):1758-1773. PMID: 32651166. <https://aacrjournals.org/cancerdiscovery/article/10/11/1758/2422/Disabled-Homolog-2-Controls-Prometastatic-Activity>

47. Lupo F., Piro G., Torroni L., Delfino P., Trovato R., Rusev B., Fiore A., Filippini D., De Sanctis F., Manfredi M., Marengo E., Lawlor R.T., Martini M., Tortora G., **Ugel S.**, Corbo V., Melisi D., Carbone C. *Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo*. *Frontiers in Cell Developmental Biology*. 2020 Apr 28;8:308. PMID: 32411709. <https://www.frontiersin.org/articles/10.3389/fcell.2020.00308/full>

48. Serafini M., Torre E., Aprile S., Del Grosso E., Gesù A., Griglio A., Colombo G., Travelli C., Paiella S., Adamo A., Orecchini O., Coletti A., Pallotta M.T., **Ugel S.**, Massarotti A., Pirali T., Fallarini S. *Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity*. *Journal of Medicinal Chemistry*. 2020 Mar 63(6), 3047-3065. <https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01809>

49. Trovato R., Canè S., Petrova V., Sartoris S., **Ugel S.**, De Sanctis F. *The Engagement Between MDSCs and Metastases: Partners in Crime*. *Frontiers in Oncology*. 2020 Feb (18): 10, 65. Review. PMID: 32133298. (corresponding authorship) <https://www.frontiersin.org/articles/10.3389/fonc.2020.00165/full>

50. Sartori G., Belluomini L., Trovato R., Minari R., Calì A., **Ugel S.**, Milella M., Pilotto S. *HER2 Aberrations in NSCLC: So Close Yet So Far*. *JCO Precision Medicine*. 2020 Nov;4:1049-1051. <https://ascopubs.org/doi/10.1200/PO.20.00195>

51. Halaby M.J., Hezaveh K., Lamorte S., Ciudad M.T., Kloetgen A., MacLeod B.L., Guo M., Chakravarthy A., Da Silva Medina T., **Ugel S.**, Tsigos A., Bronte V., Munn D.H., Pugh T.J., De Carvalho D.D., Butler M.O., Ohashi P., Brooks D.G., McGaha T.L. *GCN2 Drives Macrophage and MDSC Function and Immunosuppression in the Tumor Microenvironment*. *Science Immunology*. 2019. Dec 13: 4(42). PMID: 31836669. https://www.science.org/doi/10.1126/sciimmunol.aax8189?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed

52. Trovato R., Fiore A., Sartori S., Canè S., Giugno R., Cascione L., Paiella S., Salvia R., De Sanctis F., Poffe O., Anselmi C., Hofer F., Sartoris S., Piro G., Carbone C., Corbo V., Lawlor R., Solito S., Pinton L., Mandruzzato S., Bassi C., Scarpa A., Bronte V., **Ugel S.** *Immunosuppression by Monocytic Myeloid-Derived Suppressor Cells in Patients With Pancreatic Ductal Carcinoma Is Orchestrated by STAT3*. *Journal for Immunotherapy of Cancer*. 2019 Sep 18 7 (1), 255. PMID: 31533831. (corresponding authorship) <https://jitc.bmj.com/content/7/1/255.long>

53. Jacquelot N., Takahiro Yamazaki T., Roberti M.P., Duong C.P.M., Andrews M.C., Verlingue L., Ferrere G., Becharef S., Vétizou M., Daillère R., Messaoudene M., Enot D.P., Stoll G., **Ugel S.**, Marigo I., Ngiow S.F., Aurélien Marabelle A., Armelle Prevost-Blondel A., Gaudreau P.O., Gopalakrishnan V., Eggermont A.M., Opolon P., Klein C., Madonna G., Ascierto P.A., Sucker A., Schadendorf D., Smyth M.J., Soria J.C., Kroemer G., Bronte V., Wargo J., Zitvogel L. *Sustained Type I Interferon Signaling as a Mechanism of Resistance to PD-1 Blockade*. *Cell*

Research. 2019 Oct 29 (10), 846-861. PMID: 31481761.
<https://www.nature.com/articles/s41422-019-0224-x>

54. Canè S., **Ugel S.**, Trovato R., Marigo I., De Sanctis F., Sartoris S., Bronte V. *The Endless Saga of Monocyte Diversity*. *Frontiers in Immunology*. 2019 Aug 6. Review. PMID: 31447834.
<https://www.frontiersin.org/articles/10.3389/fimmu.2019.01786/full>
55. Filippini D., D'Agosto S., Delfino P., Simbolo M., Piro G., Rusev B., Veghini L, Cantù C., Lupo F., **Ugel S.**, De Sanctis F., Bronte V., Milella M., Tortora G., Scarpa A., Carbone C., Corbo V. *Immuno-evolution of Mouse Pancreatic Organoid Isografts From Preinvasive to Metastatic Disease*. *Scientific Reports*. 2019 Aug 9 (1), 12286. PMID: 31439856.
<https://www.nature.com/articles/s41598-019-48663-7>.
56. Bertelli G., Trovato R., **Ugel S.**, Bria E., Milella M., Bronte V., Pilotto S. *Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report*. *Clinical Lung Cancer*. 2019 Apr 28. PMID: 31122866.
<https://www.sciencedirect.com/science/article/pii/S1525730419301044?via%3Dihub>
57. Travelli C., Consonni F.M., Sangaletti S., Storto M., Morlacchi S., Grolla A.A., Galli U., Tron G.C., Portararo P., Rimassa L., Pressiani T., Mazzone M., Trovato R., **Ugel S.**, Bronte V., Tripodo C., Colombo M.P., Genazzani A.A., Sica A. *Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells*. *Cancer Research*. 2019 Feb 18. PMID: 30777853.
<https://aacrjournals.org/cancerres/article/79/8/1938/640671/Nicotinamide-Phosphoribosyltransferase-Acts-as-a>
58. Fiore A.*, **Ugel S.***, De Sanctis F., Sandri S., Fracasso G., Trovato R., Sartoris S., Solito S., Mandruzzato S., Vascotto F., Hippen K.L., Mondanelli G., Grohmann U., Piro G., Carbone C., Melisi D., Lawlor R.T., Scarpa A., Lamolinara A., Iezzi M., Fassan M., Biciato S., Blazar B.R., Sahin U., Murray P.J., Bronte V. *Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes*. *Nature Communication*. 2018 Dec 5;9(1):5193. PMID:30518925 (* equal contribution). <https://www.nature.com/articles/s41467-018-07654-4>
59. Solito S., Pinton L., De Sanctis F., **Ugel S.**, Bronte V., Mandruzzato S., Marigo I. *Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo*. *Current Protocols in Immunology*. 2018 Oct 10:e61. PMID: 30303619.
<https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/cpim.61>
60. Dugnani E., Pasquale V., Marra P., Liberati D., Canu T., Perani L., De Sanctis F., **Ugel S.**, Invernizzi F., Citro A., Venturini M., Doglioni C., Esposito A., Piemonti L. *Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound*. *Carcinogenesis*. 2018 Sep 21;39(9):1197-1206. PMID: 30052815.
<https://academic.oup.com/carcin/article/39/9/1197/5057758?login=true>

61. Boschi F., De Sanctis F., **Ugel S.**, Spinelli AE. *T-cell tracking using Cerenkov and radioluminescence imaging*. *Journal of Biophotonics*. 2018 Oct;11(10):e201800093. PMID: 29770603. <https://onlinelibrary.wiley.com/doi/10.1002/jbio.201800093>

62. De Sanctis F Sandri S., Martini M., Mazzocco M., Fiore A., Trovato R., Garetto S., Brusa D., **Ugel S.***, Sartoris S*. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens. *Vaccine*. 2018 Jun 14;36(25):3708-3716. PMID: 29752021 (* equal contribution).
<https://www.sciencedirect.com/science/article/pii/S0264410X18306170?via%3Dihub>

63. De Sanctis F., **Ugel S.**, Facciponte J., Facciabene A. *The dark side of tumor-associated endothelial cells*. *Seminars in Immunology*. 2018 Feb;35:35-47. Review.PMID:29490888.
<https://www.sciencedirect.com/science/article/pii/S1044532318300265?via%3Dihub>

64. De Sanctis F., Trovato R., **Ugel S.** *Anti-telomerase T cells adoptive transfer*. *Aging* (Albany NY). 2017 Nov 30;9(11):2239-2240.PMID: 29190214. (corresponding authorship)
<https://www.aging-us.com/article/101336/pdf>

65. Mondanelli G.*, **Ugel S. ***, Grohmann U., Bronte V. *The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO*. *Curr Opin Pharmacol*. 2017 May 26; 35:30-39. PMID:28554057.
<https://www.sciencedirect.com/science/article/pii/S1471489217300267?via%3Dihub>

66. Sandri S., De Sanctis F., Lamolinara A., Boschi F., Poffe O., Trovato R., Fiore A., Sartori S., Sbarbati A., Bondanza A., Cesaro S., Krampera M., Scupoli M.T., Nishimura M.I., Iezzi M., Sartoris S., Bronte V., **Ugel S.** *Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy*. *Oncotarget*. 2017 May 23;8(50):86987-87001. PMID: 29152058. (corresponding authorship)
<https://www.oncotarget.com/article/18115/text/>

67. Giardino A., Innamorati G., **Ugel S.**, Perbellini O., Girelli R., Frigerio I., Regi P., Scopelliti F., Butturini G., Paiella S., Bacchion M., Bassi C. *Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients*. *Pancreatology*. 2017 Sep 27: S1424-3903(17)30851-7 PMID: 29037917.
<https://www.sciencedirect.com/science/article/pii/S1424390317308517?via%3Dihub>

68. Mondanelli G., Bianchi R., Pallotta M.T., Orabona C., Albini E., Iacono A., Belladonna M.L., Vacca C., Fallarino F., Macchiarulo A., **Ugel S.**, Bronte V., Gevi F., Zolla L., Verhaar A., Peppelenbosch M., Mazza E.M., Bicciato S., Laouar Y., Santambrogio L., Puccetti P., Volpi C., Grohmann U. *A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells*. *Immunity*. 2017 Feb 21;46(2):233-244. PMID: 28214225.
<https://www.sciencedirect.com/science/article/pii/S1074761317300274?via%3Dihub>

69. Malpeli G., Barbi S., Zupo S., Tosadori G., Scardoni G., Bertolaso A., Sartoris S., **Ugel S.**, Vicentini C., Fassan M., Adamo A., Krampera M., Scupoli M.T., Croce C.M., Scarpa A. *Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53.* Oncotarget. 2017 Feb 14;8(7):11809-11826. PMID: 28107180. <https://www.oncotarget.com/article/14683/text/>

70. Marigo I., Zilio S., Desantis G., Mlecnik B., Agnellini A.H., **Ugel S.**, Sasso M.S., Qualls J.E., Kratochvill F., Zanovello P., Molon B., Ries C.H., Runza V., Hoves S., Bilocq A.M., Bindea G., Mazza E.M., Biciato S., Galon J., Murray P.J., Bronte V. *T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.* Cancer Cell. 2016 Sep 12;30(3):377-90. PMID: 27622331. <https://www.sciencedirect.com/science/article/pii/S1535610816303890?via%3Dihub>

71. De Sanctis F., Bronte V., **Ugel S.** *Tumor-Induced Myeloid-Derived Suppressor Cells.* Microbiology Spectrum. 2016 Jun;4(3). PMID:27337449. https://journals.asm.org/doi/10.1128/microbiolspec.MCHD-0016-2015?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed

72. Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.*, **Ugel S.*** *Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.* Cancer Research. 2016 May 1;76(9):2540-51. PMID: 27197263. (* equal contribution and corresponding authorship). <https://aacrjournals.org/cancerres/article/76/9/2540/618476/Feasibility-of-Telomerase-Specific-Adoptive-T-cell>

73. **Ugel S.**, De Sanctis F., Mandruzzato S., Bronte V. *Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.* Journal of Clinical Investigation. 2015 Sep;125(9):3365-76. PMID: 26325033. <https://www.jci.org/articles/view/80006>

74. **Ugel S.***, Facciponte J.G.*, De Sanctis F., Facciabene A. *Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.* Cancer Immunology Immunotherapy. 2015 Oct;64(10):1339-48. PMID: 26267042. (*equal contribution). <https://link.springer.com/article/10.1007/s00262-015-1747-8>

75. De Sanctis F., Solito S., **Ugel S.**, Molon B., Bronte V., Marigo I. *MDSCs in cancer: Conceiving new prognostic and therapeutic targets.* Biochimica et Biophysica Acta. 2016Jan;1865(1):35-48. PMID: 26255541. <https://www.sciencedirect.com/journal/biochimica-et-biophysica-acta-bba-reviews-on-cancer/vol/1865/issue/1>

76. Mazzocco M., Martini M., Rosato A., Stefani E., Matucci A., Dalla Santa S., De Sanctis F., **Ugel S.**, Sandri S., Ferrarini G., Cestari T., Ferrari S., Zanovello P., Bronte V., Sartoris S. *Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.* Immunology.

77. Ricci C., Mota C., Moscato S., D'Alessandro D., **Ugel S.**, Sartoris S., Bronte V., Boggi U., Campani D., Funel N., Moroni L., Danti S. *Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models.* *Biomatter*. 2014;4:e955386. PMID: 25482337.
<https://www.tandfonline.com/doi/full/10.4161/21592527.2014.955386>
78. Facciponte J.G.*, **Ugel S.** *, De Sanctis F., Li C, Wang L., Nair G., Sehgal S., Raj A., Matthaïou E., Coukos G., Facciabene A. *Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.* *Journal of Clinical Investigation*. 2014 Apr;124(4):1497-511. PMID: 24642465. (* equal contribution). <https://www.jci.org/articles/view/67382>
79. De Sanctis F., Sandri S., Ferrarini G., Pagliarello I., Sartoris S., **Ugel S.**, Marigo I., Molon B., Bronte V. *The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.* *Frontiers in Immunology*. 2014 Feb 24;5:69. PMID: 24605112. <https://www.frontiersin.org/articles/10.3389/fimmu.2014.00069/full>
80. **Ugel S.***, Peranzoni E.*, Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S., Bronte V. *Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.* *Cell Reports*. 2012 Sep 27;2(3):628-39. PMID: 22959433. (* equal contribution).
<https://www.sciencedirect.com/science/article/pii/S2211124712002318?via%3Dihub>
81. Molon B.*, **Ugel S.***, Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., Savino B., Colombo P., Jonjic N., Pecanic S., Lazzarato L., Fruttero R., Gasco A., Bronte V., Viola A. *Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.* *Journal of Experimental of Medicine*. 2011 Sep 26;208(10):1949-62. PMID:21930770. (* equal contribution).
<https://rupress.org/jem/article/208/10/1949/40937/Chemokine-nitration-prevents-intratumoral>
82. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., **Ugel S.**, Sonda N., Biciato S., Falisi E., Calabrese F., Basso G., Zanovello P., Cozzi E., Mandruzzato S., Bronte V. *Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.* *Immunity*. 2010 Jun 25;32(6):790-802. PMID: 20605485.
<https://www.sciencedirect.com/science/article/pii/S1074761310002025?via%3Dihub>
83. Martini M., Testi M.G., Pasetto M., Picchio M.C., Innamorati G., Mazzocco M., **Ugel S.**, Cingarlini S., Bronte V., Zanovello P., Krampera M., Mosna F., Cestari T., Riviera A.P., Brutti N., Barbieri O., Matera L., Tridente G., Colombatti M., Sartoris S. *IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.* *Vaccine*. 2010 Apr 30;28(20):3548-57. PMID: 20304037.
<https://www.sciencedirect.com/science/article/pii/S0264410X10003439?via%3Dihub>

84. Dolcetti L., Peranzoni E., **Ugel S.**, Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., Grassi F., Bronte V. *Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.* European Journal of Immunology. 2010 Jan;40(1):22-35. PMID: 19941314.
<https://onlinelibrary.wiley.com/doi/10.1002/eji.200939903>

85. **Ugel S.***, Zoso A.*, De Santo C.*, Li Y., Marigo I., Zanovello P., Scarselli E., Cipriani B., Oelke M., Schneck J.P., Bronte V. *In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.* Cancer Research. 2009 Dec 15;69(24):9376-84. PMID: 19934317. (* equal contribution).
<https://aacrjournals.org/cancerres/article/69/24/9376/551081/In-vivo-Administration-of-Artificial-Antigen>

86. **Ugel S.***, Scarselli E.*, Iezzi M., Mennuni C., Pannellini T., Calvaruso F., Cipriani B., De Palma R., Ricci-Vitiani L., Peranzoni E., Musiani P., Zanovello P., Bronte V. *Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.* Blood. 2010 Feb 18;115(7):1374-84. PMID: 19903903. (* equal contribution).
<https://ashpublications.org/blood/article/115/7/1374/26711/Autoimmune-B-cell-lymphopenia-after-successful>

87. **Ugel S.**, Delpozzo F., Desantis G., Papalini F., Simonato F., Sonda N., Zilio S., Bronte V. *Therapeutic targeting of myeloid-derived suppressor cells.* Current Opinion in Pharmacology. 2009 Aug;9(4):470-81. PMID:19616475.
<https://www.sciencedirect.com/science/article/pii/S1471489209000873?via%3Dihub>

88. Mennuni C.*, **Ugel S.***, Mori F., Cipriani B., Iezzi M., Pannellini T., Lazzaro D., Ciliberto G., La Monica N., Zanovello P., Bronte V., Scarselli E. *Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.* Cancer Research. 2008 Dec 1;68(23):9865-74. PMID: 19047167. (* equal contribution).
<https://aacrjournals.org/cancerres/article/68/23/9865/540757/Preventive-Vaccination-with-Telomerase-Controls>

89. Peranzoni E., Marigo I., Dolcetti L., **Ugel S.**, Sonda N., Taschin E., Mantelli B., Bronte V., Zanovello P. *Role of arginine metabolism in immunity and immunopathology.* Immunobiology. 2007;212(9-10):795-812. PMID:18086380.
<https://www.sciencedirect.com/science/article/pii/S0171298507001131?via%3Dihub>

90. Bronte V., Cingarlini S., Marigo I., De Santo C., Gallina G., Dolcetti L., **Ugel S.**, Peranzoni E., Mandruzzato S., Zanovello P. *Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.* Immunological Investigation. 2006;35(3-4):327-57. PMID: 16916757.
<https://www.tandfonline.com/doi/full/10.1080/08820130600754994>

Author Position

First author: **17%**

Last author: **18%**

Corresponding author: **13%**

Co-author: **63%**

Single author: **0%**

Dr. Stefano Ugel bibliometric indexes are

SCOPUS:

Documenti: 94

Hirsch h index: 38

Citations: 6517

<https://www.scopus.com/>

Web of Science

Documenti: 99

Hirsch h index: 37

Citations: 6112

http://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_mode=GeneralSearch&SID=Q2nhFMu6oynPK5ojF9M&preferencesSaved=

Google Scholar

Documenti: 126

Hirsch h index: 41

Citations: 8702

<https://scholar.google.it/>

Member Status

Member of the Italian Network for Biotherapy of cancer (NIBIT).

Member of Società Italiana di Cancerologia (SIC).

Member of Società Italiana per l'Analisi Citometrica Cellulare (ISCCA).

Member of Società Italiana di Immunologia, Immunologia Clinica ed Allergologica (SIICA).

Member of Società Italiana di Ematologia Sperimentale (SIES).

Member of Associazione Italiana per le Scienze degli Animali da Laboratorio (AISAL).

Member of Associazione Italiana Di Colture Cellulari (AICC).

Editorial board and Reviewer activity

2016– Frontiers in Immunology

169 certified revisions (<https://www.webofscience.com/wos/author/record/J-5535-2016>) as reported by Web Of Science: Frontiers in Immunology, Cancer Immunology Research, Nature Communications, Molecular Immunology, Tumor Biology, Cells, Oncogene, Cancers, Biomaterials,

Scientific Reports, Cell Death and Disease, Biochimica et Biophysica Acta (BBA), Cancers, International Immunopharmacology, Current Opinion in Immunology, Molecular Therapy, Drug Discovery Today, Frontiers in Pharmacology, Frontiers in Molecular Biosciences, Atherosclerosis, Biomedicines, Heliyon, Immunologic Research, Journal for Immunotherapy of Cancer, Signal Transduction and Targeted Therapy, Molecular Therapy – Oncolytics, Discover Oncology, Life Sciences, Cellular and Molecular Neurobiology, Journal of Advanced Research, Cytotherapy, Clinical Epigenetics.

Commission of Trust

2018_Peer Reviewer for Kom op tegen Kanker, Bruxel, Belgium.

2019_Member of the commission for Research evaluation for University of Brescia, Italy.

2020_Peer Reviewer for WorldWide Cancer Research Grants, United Kingdom.

2020_Peer Reviewer for Swiss National Science Foundation, Switzerland.

2022_Peer Reviewer for Narodowe Centrum Nauki, Poland.

2022_President of the commission for competition notice for technicians (Cod. 2022ctecpev003), University of Verona, Italy.

2022_Member of the selection committee for a researcher position RTD-A (MED/04 General Pathology) for University of Padova, Italy.

2022_President of the selection committee for a researcher position RTD-A (MED/04 General Pathology) for University of Verona, Italy.

2022_Member of the selection committee for PhD selection for the course Inflammation, Immunity and Cancer, for University of Verona, Italy.

2023_Member of the selection committee for a researcher position RTD-A (MED/04 General Pathology) for University of Torino, Italy.

2023_Peer Reviewer for the French National Cancer Institute, France

2023_Peer Reviewer for the Agency for Science, Technology and Research (A*STAR) under the Singapore Ministry of Trade and Industry (MTI) and the Directorate General for Country Promotion of the Italian Ministry of Foreign Affairs and International Cooperation (MAECI), Singapore/Italy

2023_Peer Reviewer for the Executive Board of the Austrian Science Fund (FWF), Austria

2023_Member of the evaluation committee for researchers of Istituto Oncologico Veneto (IOV), Italy.

2023_Peer Reviewer for the Executive Board della Fondazione Cariplo, Italia.

2023_Member of the selection committee for a researcher position RTD-B, University of Torino, Italy.

2023_Member of the selection committee for a researcher position RTD-B, University of Piemonte Orientale, Italy.

2024_Peer Reviewer for the Executive Board of the Austrian Science Fund (FWF), Austria

2024_Peer Reviewer for The Swiss National Science Foundation, Switzerland.

2024_Peer Reviewer for BONFOR Research Funding Programme, University of Bonn, Germany.

2024_Peer Reviewer for the French National Cancer Institute, France.

2024_Member of the commission for the final discussion of PhD course in Clinical Oncology and Experimental immunology (Cicle XXXVI), University of Padova, Italy.

2024_Member of the selection committee for PhD selection for the course Inflammation, Immunity and Cancer, for University of Verona, Italy.

2024_External reviewer and member of the commission for the final discussion of the PhD candidate Ines Lecoq Molinos at the Faculty of Health and Medical Science, University of Copenhagen, Denmark.

2025_Member of the commission for the final discussion of PhD course in Clinical Oncology and Experimental immunology (Ciclo XXXVII), University of Padova, Italy.

2025_Peer Reviewer for French National Cancer Institute, France.

2025_Peer Reviewer for Swiss Cancer Research, Switzerland.

2025_External reviewer and member of the commission for the final discussion of the PhD candidate Eline Janssen at the Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands.

2025_Peer Reviewer for Worldwide Cancer Research Grant Applications 2025, 10 Canning Street, Edinburgh, United Kingdom (UK).

2025_Member of the selection committee for PhD selection for the course Inflammation, Immunity and Cancer, for University of Verona, Italy.

2025_Member of the selection committee for a researcher position RTT, University of Padova (Decreto Rettorale n. 559 del 7 febbraio 2025).

2025_Scientific Reviewer for the Call for Proposals of IOV-Istituto Oncologico Veneto-"Seed Grants for Novel Research Ideas Call for Proposals 2025

Responsibility for research projects involving animal testing

1. Authorization no. 99/2020-PR issued by the Ministry of Health for the implementation of the project entitled: "*Study of the function of the FLIP protein in the onset and progression of solid and liquid tumors*", acquired with protocol. C46F4.26 dated 07/24/2020 and integration dated 09/14/2020, valid for 60 months starting from 09/17/2020 (expires 09/16/2025).
2. Authorization no. 227/2023-PR issued by the Ministry of Health for the implementation of the project entitled: "Definition of the molecular processes of immune evasion during tumor progression and the formation of metastases", acquired with protocol. C46F4.30 dated 09/22/2022 and integration dated 03/10/2023, valid for 60 months starting from 03/14/2023 (expires 03/13/2028)

THIRD MISSION and DISSEMINATION ACTIVITY FOR A GENERAL PUBLIC

- AIRC incontra la popolazione 2017_ Programma Culturale Formativo Vestenanova 2017. Titolo: Conoscere il tumore per prevenirlo, diagnosticarlo e curarlo in tempo.
- AIRC nelle Scuole 2019_ Istituto Comprensivo Carlotta Aschieri, San Pietro in Cariano (VR). Titolo: Nel mondo della ricerca con il Prof. Stefano Ugel.
- AIRC nelle Scuole 2022_ Istituto Comprensivo di Longarone (BL). Titolo: Nel mondo della ricerca con il Prof. Stefano Ugel.

- UNIVAX 2022 promosso da SIICA. Titolo: Ricordare per difendersi meglio. (<https://www.youtube.com/watch?v=yCI8MoSC2pA&t=3907s>).
- UNIVAX 2023 promosso da SIICA. Titolo: La memoria immunitaria.
- UNIVAX 2024 promosso da SIICA. Titolo: Il sistema immunitario e l'arte di ricordare.
- UNIVAX 2025 promosso da SIICA. Titolo: L'alchimia del sistema immunitario.

DIDACTIC ACTIVITY

Teaching activity University of Verona:

1. 2016-2017 and 2020-up now: Professor of Immunology at the course of Combined Bachelor's + Master's degree in Dentistry and Dental Prosthetics, University of Verona (Italy);
2. 2016-2018 and 2022-up now: Professor of Immunology in the course of Bachelor's degree in Biomedical Laboratory Techniques (to qualify as a biomedical laboratory worker), University of Verona (Italy);
3. 2017-up now: Professor of Sciences introduction to the medical profession at course of Combined Bachelor's + Master's degree in Medicine and Surgery, University of Verona (Italy);
4. 2017-up now: Professor of Systematic pathology I at the course of Combined Bachelor's + Master's degree in Medicine and Surgery, University of Verona (Italy);
5. 2017-up now: Professor of Immunology in the course of Bachelor's degree in Biotechnology, University of Verona (Italy);
6. 2020-2025: Professor of Immunology in the course of Surgical and Medical Sciences at the University of Trento (Italy);
7. 2021-2023: Professor of Immunopathology in the course of Bachelor's degree in Biomedical Laboratory Techniques (to qualify as a biomedical laboratory worker), University of Verona (Italy);
8. 2022-2024: Professor of Immunopathology in the course of Surgical and Medical Sciences at the University of Trento (Italy)
9. 2022-up now: Professor of Immunology at the course of Combined Bachelor's + Master's degree in Medicine and Surgery, University of Verona (Italy);

Academic Assignments:

- 1) Council member for the Degree Course in Biomedical Laboratory Techniques - Medicine and Surgery; Department of Medicine, University of Verona.
- 2) Council member for the PhD program Inflammation, Immunity and Cancer; Department of Medicine, University of Verona
- 3) Council member for the Degree in Biotechnology, Department of Biotechnology, University of Verona
- 4) Council member of Grad School of Allergology and Immunology, Department of Medicine, University of Verona
- 5) Council member (L2) of Department of Medicine, University of Verona
- 6) Scientific Member of OPBA (Animal Welfare Council) as elected representative of the Department of Medicine (2022-up to now)

7) Research Quality Assurance Officer (AQ) for the Department of Medicine (2024-up to now)

Academic Commission of the PhD course:

1. Member of the commission for the final evaluation of PhD students of the Inflammation, Immunity and Cancer course (a.a.2018-2019), University of Verona, Italy.
2. Member of the commission for the final evaluation of PhD students of the Biomedical Science course (a.a.2022-2023), University of Padova, Italy.
3. Member of the commission for the final evaluation of PhD students of the Biomedical Science and Translational Medicine course (a.a.2018-2019), University of Brescia, Italy.

Academic Commission of Bachelor's/Master's Degree :

1. Member of the commission for the final evaluation of the Master's degree in Medicine and Surgery (a.a. 2016-2017)
2. Member of the commission for the final evaluation of the Master's degree in Molecular and Medical Biotechnology (a.a. 2016-2017)
3. Member of the commission for the final evaluation of the Master's degree in Dentistry and Dental Prosthetics (a.a. 2016-2017)
4. Member of the commission for the final evaluation of the Bachelor's degree in Biotechnology (a.a. 2018-2019)
5. Member of the commission for the final evaluation of the Bachelor's degree in Biotechnology (a.a. 2019-2020)
6. Member of the commission for the final evaluation of the Bachelor's degree in Biotechnology (a.a. 2020-2021)
7. Member of the commission for the final evaluation of the Bachelor's degree in Biotechnology (a.a. 2021-2022)
8. Member of the commission for the final evaluation of the Bachelor's degree in Biotechnology (a.a. 2022-2023)
9. Member of the commission for the final evaluation of the Master's degree in Surgical and Medical Sciences (a.a. 2022-2023)
10. Member of the commission for the final evaluation of the Master's degree in Surgical and Medical Sciences (a.a. 2024-2025)

Mentoring and Tutor activity:

Supervisor of research activity:

- 2019: Supervisor of **Alberto Utero Urico** (Spain) as winner of EFIS Board Fellowship 2019 (6 months).
- 219: Supervisor of **Hiroshi Tsujii** (Japan), as winner of Erasmus Traineeship Fellowship 2019 (2 months)
- 2020-2023: Supervisor of **Annalisa Adamo** (Italy) as winner of AIRC Post-Doc Fellowship (3 years) entitled: "Unveiling the role of c-FLIP and c-FLIP-expressing immunosuppressive

myeloid cells in non-small-cell lung carcinoma” at the Immunology Section of the Department of Medicine, University of Verona (Italy).

- 2021-2023: Supervisor of **Fang Qi** (China), as a winner of an international fellowship supported by the China Scholarship Council 2021
- 2023: Supervisor of **Chiara Musiu** (Italy) as winner of AIRC Post-Doc Fellowship (1 year) entitled: “Characterization of cancer-dependent reprogramming to generate pro-metastatic myeloid cells: from humanized preclinical” at the Immunology Section of the Department of Medicine, University of Verona (Italy).
- 2024: Supervisor of **Chiara Musiu** (Italy) as winner of Fondazione Veronesi Fellowship (1 year) entitled: “Charting the altered myelopoiesis in human cancer” at the Immunology Section of the Department of Medicine, University of Verona (Italy).
- 2025-2026: Supervisor of **Xingyan Liu** (China), as a winner of an international fellowship supported by the China Scholarship Council 2021

Supervisor of PhD students:

- 2012-2014: Tutor of **Giovanna Ferrarini** PhD student enrolled at the Translational Medicine Course of the PhD Medicine School of the University of Verona (Italy);
- 2020-2022: Tutor of **Tian Wang** PhD student enrolled at the Inflammation, Immunity and Cancer Course of the PhD Medicine School of the University of Verona (Italy);
- 2022-2024: Tutor of **Elia Urbini**, PhD student enrolled at the Inflammation, Immunity and Cancer Course of the PhD Medicine School of the University of Verona (Italy);
- 2022-2024: Tutor of **Nicolas Binetti** PhD student enrolled at the Inflammation, Immunity and Cancer Course of the PhD Medicine School of the University of Verona (Italy);
- 2022-2024: Tutor of **Hu Yushu**, PhD student enrolled at the Inflammation, Immunity and Cancer Course of the PhD Medicine School of the University of Verona (Italy);
- 2024-2026: Tutor of **Luca Giacobazzi**, PhD student enrolled at the Inflammation, Immunity and Cancer Course of the PhD Medicine School of the University of Verona (Italy);

Supervisor/ co-supervisor of University students:

1. 2008: Assistant supervisor of Dr.ssa **Pamela Biondani**, master's degree (110/110 summa cum laude) in Surgical and Medical Sciences at the University of Padova (Italy);
2. 2009: Assistant supervisor of Dr.ssa **Sara Bisetto**, bachelor's degree (108/110) in Pharmacology at the University of Padova (Italy);
3. 2014: Assistant supervisor of Dr.ssa **Lorena Cristovao Borges**, bachelor's degree (102/110) in Biotechnology at the University of Verona (Italy);
4. 2014: Assistant supervisor of Dr. **Daniele Pellegrini**, bachelor's degree (98/110) in Biotechnology at the University of Verona (Italy);
5. 2015: Assistant supervisor of Dr. **Barbara Zerbato**, bachelor's degree (100/110) in Biotechnology at the University of Verona (Italy);
6. 2015: Assistant supervisor of Dr. **Giulia Barban**, bachelor's degree (106/110) in Biotechnology at the University of Verona (Italy);

7. 2016: Assistant supervisor of Dr. **Lorenzo Bombarda**, bachelor's degree (90/110) in Biotechnology at the University of Verona (Italy);
8. 2016: Supervisor of Dr. **Andrea Terranera**, master's degree (110/110) in Biotechnology at the University of Verona (Italy);
9. 2017: Supervisor of Dr. **Sebastiano Dalla Gassa**, bachelor's degree (97/110) in Biotechnology at the University of Verona (Italy);
10. 2017: Supervisor of Dr. **Ottavia Salvi Bentivoglio**, bachelor's degree (101/110) in Biotechnology at the University of Verona (Italy);
11. 2017: Assistant supervisor of Dr. **Anna Reni**, master's degree (110/110 summa cum laude) in Surgical and Medical Sciences at the University of Verona (Italy);
12. 2017: Supervisor of Dr. **Martina Spiga**, bachelor's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
13. 2018: Supervisor of Dr. **Nicolò Martinelli**, bachelor's degree (100/110) in Biotechnology at the University of Verona (Italy);
14. 2017: Assistant supervisor of Dr. **Giacomo Bertelli**, master's degree (110/110 summa cum laude) in Surgical and Medical Sciences at the University of Verona (Italy);
15. 2019: Supervisor of Dr. **Letizia Bertagnin**, bachelor's degree (93/110) in Biotechnology at the University of Verona (Italy);
16. 2019: Supervisor of Dr. **Benedetta Carlesso**, bachelor's degree (96/110) in Biotechnology at the University of Verona (Italy);
17. 2019: Assistant supervisor of Dr. **Nicolò Rascidi**, master's degree (110/110 summa cum laude) in Surgical and Medical Sciences at the University of Verona (Italy);
18. 2019: Supervisor of Dr. **Anna Vareschi**, bachelor's degree (105/110) in Biotechnology at the University of Verona (Italy);
19. 2019: Supervisor of Dr. **Francesca Pesavento**, bachelor's degree (108/110) in Biomedical Laboratory Techniques at the University of Verona (Italy);
20. 2020: Supervisor of Dr. **Federica Fusato**, bachelor's degree (108/110) in Biotechnology at the University of Verona (Italy);
21. 2020: Supervisor of Dr. **Tommaso Grandi**, bachelor's degree (108/110) in Biotechnology at the University of Verona (Italy);
22. 2020: Supervisor of Dr. **Gianmarco Tarquini**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
23. 2020: Supervisor of Dr. **Alessia Crema**, bachelor's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
24. 2020: Supervisor of Dr. **Erika Spagnoli**, bachelor's degree (104/110) in Biotechnology at the University of Verona (Italy);
25. 2021: Supervisor of Dr. **Sara Spada**, bachelor's degree (103/110) in Biotechnology at the University of Verona (Italy);
26. 2021: Supervisor of Dr. **Andreas Zomer**, bachelor's degree (100/110) in Biotechnology at the University of Verona (Italy);
27. 2021: Supervisor of Dr. **Alice Passarini**, bachelor's degree (96/110) in Biotechnology at the University of Verona (Italy);
28. 2021: Supervisor of Dr. **Lorenzo Panelatti**, bachelor's degree (105/110) in Biotechnology at the University of Verona (Italy);


29. 2021: Assistant supervisor of Dr. **Silvia Brazzarola**, bachelor's degree (108/110) in Biotechnology at the University of Ferrara (Italy);
30. 2021: Supervisor of Dr. **Davide Rizzini**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
31. 2021: Supervisor of Dr. **Alberto Atanasio**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
32. 2021: Assistant supervisor of Dr. **Laura De Grandi**, master's degree (110/110 summa cum laude) in Surgical and Medical Sciences at the University of Verona (Italy);
33. 2022: Supervisor of Dr. **Chiara Dalgai**, bachelor's degree (107/110) in Biotechnology at the University of Verona (Italy);
34. 2022: Supervisor of Dr. **Valeria Facchinelli**, bachelor's degree (102/110) in Biotechnology at the University of Verona (Italy);
35. 2023: Supervisor of Dr. **Francesco Conati**, bachelor's degree (103/110) in Biotechnology at the University of Verona (Italy);
36. 2023: Supervisor of Dr. **Matteo Farinazzo**, bachelor's degree (104/110) in Biotechnology at the University of Verona (Italy);
37. 2023: Supervisor of Dr. **Isabella Vaccari**, bachelor's degree (94/110) in Biotechnology at the University of Verona (Italy);
38. 2023: Supervisor of Dr. **Giulia Vincenzi**, bachelor's degree (99/110) in Biotechnology at the University of Verona (Italy);
39. 2023: Assistant supervisor of Dr. **Gian Marco Ciresola**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
40. 2023: Supervisor of Dr. **Marco Moneta**, bachelor's degree (100/110) in Biotechnology at the University of Verona (Italy);
41. 2023: Supervisor of Dr. **Elisa Maggio**, bachelor's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
42. 2023: Supervisor of Dr. **Loriana Laska**, bachelor's degree (103/110) in Biomedical Laboratory Techniques at the University of Verona (Italy);
43. 2023: Supervisor of Dr. **Aurora Avancini**, master's degree (110/110 summa cum laude) in Surgical and Medical Sciences at the University of Verona (Italy);
44. 2023: Supervisor of Dr. **Micaela Sanfilippo**, master's degree (93/110) in Biotechnology at the University of Verona (Italy);
45. 2024: Supervisor of Dr. **Lorenzo Zimelli**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
46. 2024: Supervisor of Dr. **Luca Giacobazzi**, master's degree (108/110) in Biotechnology at the University of Verona (Italy);
47. 2024: Supervisor of Dr. **Francesca Tregnaghi**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
48. 2024: Supervisor of Dr. **Giuseppe Scirocco**, master's degree (108/110) in Biotechnology at the University of Verona (Italy);
49. 2024: Supervisor of Dr. **Mosè Montolli**, bachelor's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
50. 2025: Supervisor of Dr. **Isabella Vaccari**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);

51. 2025: Supervisor of Dr. **Annalisa Torracca**, master's degree (110/110 summa cum laude) in Biotechnology at the University of Verona (Italy);
52. 2025: Supervisor of Dr. **Francesco Conati**, master's degree (106/110) in Biotechnology at the University of Verona (Italy);
53. 2025: Supervisor of Dr. **Elena Battaglin**, bachelor's degree (109/110) in Biotechnology at the University of Verona (Italy);
54. 2025: Supervisor of Dr. **Martina Gabriella Barone**, bachelor's degree (109/110) in Biotechnology at the University of Verona (Italy);
55. 2025: Supervisor of Dr. **Nicole Robol**, bachelor's degree (105/110) in Biotechnology at the University of Verona (Italy);

Il sottoscritto dichiara che quanto contenuto nel presente documento corrisponde al vero. Le dichiarazioni rese nel presente documento sono rilasciate ai sensi degli articoli 46 e 47 del D.P.R. 445/2000.

Verona, 22 December 2024

Prof. Stefano Ugel, PhD


Prof. Stefano Ugel
Università degli Studi di Verona
Sezione di Immunologia